The latest treatments for thyroid cancer, particularly advanced or metastatic papillary thyroid cancer with RET mutations resistant to radioactive iodine, include targeted therapies like selpercatinib (Retevmo) and pralsetinib (Gavreto).
Targeted Therapies for RET-Mutated Thyroid Cancer
Recent advancements in thyroid cancer treatment focus on targeted therapies that address specific genetic mutations. These therapies are particularly useful for patients with advanced or metastatic papillary thyroid cancer that has a RET mutation and no longer responds to radioactive iodine.
Selpercatinib (Retevmo)
- Mechanism: Selpercatinib is a selective RET kinase inhibitor. It works by blocking the activity of the altered RET protein, thereby slowing or stopping cancer cell growth.
- Target Population: Patients with advanced or metastatic RET-mutant papillary thyroid cancer resistant to radioactive iodine.
Pralsetinib (Gavreto)
- Mechanism: Similar to selpercatinib, pralsetinib is a RET inhibitor that selectively targets RET alterations to prevent cancer cell proliferation.
- Target Population: Used in patients with advanced or metastatic RET-mutant papillary thyroid cancer that is resistant to radioactive iodine therapy.
These targeted therapies represent a significant advancement in treating specific types of thyroid cancer, offering hope for patients who have exhausted other treatment options. It's essential for patients to undergo genetic testing to determine if they have a RET mutation and are eligible for these treatments. Always consult with an oncologist for personalized medical advice and treatment plans.
